142 related articles for article (PubMed ID: 12480692)
1. Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis.
Asosingh K; De Raeve H; Van Riet I; Van Camp B; Vanderkerken K
Blood; 2003 Apr; 101(8):3136-41. PubMed ID: 12480692
[TBL] [Abstract][Full Text] [Related]
2. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294
[TBL] [Abstract][Full Text] [Related]
3. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.
Asosingh K; De Raeve H; Croucher P; Goes E; Van Riet I; Van Camp B; Vanderkerken K
Exp Hematol; 2001 Jan; 29(1):77-84. PubMed ID: 11164108
[TBL] [Abstract][Full Text] [Related]
4. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.
Yaccoby S
Clin Cancer Res; 2005 Nov; 11(21):7599-606. PubMed ID: 16278377
[TBL] [Abstract][Full Text] [Related]
5. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
Frassanito MA; Cusmai A; Iodice G; Dammacco F
Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
[TBL] [Abstract][Full Text] [Related]
6. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model.
Asosingh K; Willems A; Van Riet I; Van Camp B; Vanderkerken K
Cancer Res; 2003 Jun; 63(12):3019-20. PubMed ID: 12810619
[TBL] [Abstract][Full Text] [Related]
7. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.
Asosingh K; Menu E; Van Valckenborgh E; Vande Broek I; Van Riet I; Van Camp B; Vanderkerken K
Clin Exp Metastasis; 2002; 19(7):583-91. PubMed ID: 12498387
[TBL] [Abstract][Full Text] [Related]
11. Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity.
Asosingh K; De Raeve H; Menu E; Van Riet I; Van Marck E; Van Camp B; Vanderkerken K
Blood; 2004 Apr; 103(8):3131-7. PubMed ID: 15070695
[TBL] [Abstract][Full Text] [Related]
12. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
13. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.
Seidel C; Børset M; Hjertner O; Cao D; Abildgaard N; Hjorth-Hansen H; Sanderson RD; Waage A; Sundan A
Blood; 2000 Nov; 96(9):3139-46. PubMed ID: 11049995
[TBL] [Abstract][Full Text] [Related]
14. In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.
Rawstron AC; Barrans SL; Blythe D; English A; Richards SJ; Fenton JA; Davies FE; Child JA; Jack AS; Morgan GJ
Br J Haematol; 2001 Jun; 113(3):794-802. PubMed ID: 11380472
[TBL] [Abstract][Full Text] [Related]
15. Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.
Pilarski LM; Seeberger K; Coupland RW; Eshpeter A; Keats JJ; Taylor BJ; Belch AR
Exp Hematol; 2002 Mar; 30(3):221-8. PubMed ID: 11882359
[TBL] [Abstract][Full Text] [Related]
16. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
17. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
18. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B
Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094
[TBL] [Abstract][Full Text] [Related]
19. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation.
Dhodapkar MV; Abe E; Theus A; Lacy M; Langford JK; Barlogie B; Sanderson RD
Blood; 1998 Apr; 91(8):2679-88. PubMed ID: 9531576
[TBL] [Abstract][Full Text] [Related]
20. Purging of myeloma cells using all-trans retinoic acid in a mouse model.
Henry JM; Morley AA; Sykes PJ
Exp Hematol; 2001 Mar; 29(3):315-21. PubMed ID: 11274759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]